SCHEMBL30983443

SCHEMBL30983443

Cc1ccc(Cn2c(-c3ccc(OCCN4CCNCC4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.38
▸ HRH4 Q9H3N8 5/20 0.37
▸ DRD2 P14416 4/20 0.35
▸ SIGMAR1 Q99720 1/20 0.33
▸ ALK Q9UM73 1/20 0.33
▸ PRKAB2 O43741 1/20 0.33
▸ PRKAG1 P54619 1/20 0.33
▸ PRKAA2 P54646 1/20 0.33
▸ PRKAA1 Q13131 1/20 0.33
▸ PRKAG3 Q9UGI9 1/20 0.33
▸ PRKAG2 Q9UGJ0 1/20 0.33
▸ PRKAB1 Q9Y478 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PIK3CD O00329 1/20 0.32
▸ ESR1 P03372 3/20 0.32
▸ ESR2 Q92731 3/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ SCN9A Q15858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983407 0.95 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269261 0.94 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269151 0.94 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31268861 0.93 PDE2A (0.36) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269262 0.92 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269308 0.92 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983467 0.91 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983522 0.91 PDE2A (0.41) PDE2AHRH4DRD2ALKKDM4E
SCHEMBL31269127 0.91 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269312 0.91 HRH4 (0.38) PDE2AHRH4DRD2SIGMAR1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB PDE2A 1118/4885HRH4 4696/4885DRD2 3087/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB PDE2A 1118/4885HRH4 4696/4885DRD2 3087/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB PDE2A 1118/4885HRH4 4696/4885DRD2 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback